Genetic Technologies Limited · ASX:GTG
Genetic Technologies — H.C. Wainwright 23rd Annual Global Investment Conference (September 2021)
31 slides from Genetic Technologies's conference presentation, Sep 13, 2021
Slide 1: H.C. Wainwright 23rd Annual Global Investment Conference
H.C. Wainwright 23rd Annual Global Investment Conference 13 – 15 September 2021 ASX: GTG Authorised by the Board of Directors of Genetic Technologies Limited NASDAQ: GENE
Slide 2: Notice: Forward looking statements
Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require fu
Slide 3: Our Overview
Our Overview 01 02 03 04 05 06 Our Vision & Our Markets Our Acquisition Our Channels & Our Portfolio & Our Capabilities Brand Pillars Divisions Innovation 2021 Overview Prioritising the EasyDNA - Building our Focused on three Executing through cutting Aligning our internal Where are market entry Dir
Slide 4: Unlocking personalised preventative health
Unlocking personalised preventative health Significant progress has been made in understanding the role of hereditary risk in chronic disease, however, many chronic conditions cannot be predicted by this risk alone. We’re transforming the conversation. Transitioning from a one-size-fits-all model to
Slide 5: geneType's brand evolution reflects its commitment to personalised, preventative health care
geneType’s brand evolution reflects its commitment to personalised, preventative health care Unequalled experience Leading integrated technology Scientific team leveraging their extensive research The sophisticated integration of genomic and clinical track record in breast and colorectal to expand o
Slide 6: Our 2021 Snapshot
Our 2021 Snapshot Signed multi-year distribution agreement Acquired revenue generating platform License and distribution agreement for COVID-19 Acquired EasyDNA for US$4m in cash and script2 Risk Test with IBX for minimum of US$2.9 million providing global platform with US$4.63m in over 3 years to m
Slide 7: Our Vision & Brand Pillars
01 02 03 04 05 06 Our Vision & Our Markets Our Acquisition Our Channels & Our Portfolio & Our Capabilities Brand Pillars Divisions Innovation 7
Slide 8: Our Markets and Collaborators
Our Markets and Collaborators United States Europe & UK Asia Australia & New Zealand (Inc. SEA, China and India) geneType® Polygenic Risk Commencing CE certification H2 CY2021 to commence a Certification by Australian Score (PRS) tests for breast, enabling EU launch of Novel scoping and Prioritising
Slide 9: A strategy to own the personalised, preventative health testing market
A strategy to own the personalised, preventative health testing market Brand Recognition and Advocacy Commercialization and Branding Thought leadership Sales & marketing Demonstrating our leadership by informing the Core set of sales and marketing tactics and assets conversation on personalised, pre
Slide 10: A cutting-edge geneType brand set for relaunch
A cutting-edge geneType brand set for relaunch Digital Mobile Education
Slide 11: Our Acquisition
01 02 03 04 05 06 Our Vision & Our Markets Our Acquisition Our Channels & Our Portfolio & Our Capabilities Brand Pillars Divisions Innovation 11
Slide 12: EasyDNA – Acquisition of DTC Platform
EasyDNA – Acquisition of DTC Platform • Acquired EasyDNA in August 2021 for US$4 million • Current revenues of US$4.63 million through retail sales of its at- home DNA tests • Agreements with 12 laboratories in North America, AsiaPac and Europe • A platform to launch the geneType Multi Test and port
Slide 13: EasyDNA – Establishing our Lifestyle Division
EasyDNA – Establishing our Lifestyle Division • Headed by Kevin Camilleri • EasyDNA currently sells paternity, oncology and health and wellbeing genomics-based tests • This acquisition provides Genetic Technologies the foundation to grow in 40 countries • Expand the health related tests with an exte
Slide 14: Our Channels & Divisions
01 02 03 04 05 06 Our Vision & Our Markets Our Acquisition Our Channels & Our Portfolio & Our Capabilities Brand Pillars Divisions Innovation 14
Slide 15: Our Pathways
Our Pathways Medical – Business to Business Consumer initiated testing (CIT) Direct to consumer testing (DTC) (B2B) with medical supervision with no medical supervision A communication Certifying Launched US and Current products Recent Acquisition Provides Genetic and execution plan reimbursable Aus
Slide 16: Our Divisions
Our Divisions Emerging divisions Pharmoco- Oncology Genetics & Existing divisions BC, CRC, PC, Companion NEW – Universal collection test kit Melanoma diagnostics to support Multi Test Launch CVD Germline testing (Heart Disease) BRCA, Lynch IHD, AF Syndrome and Somatic testing COVID-19 Mental Health
Slide 17: Our Portfolio & Innovation
01 02 03 04 05 06 Our Vision & Our Markets Our Acquisition Our Channels & Our Portfolio & Our Capabilities Brand Pillars Divisions Innovation 18
Slide 18: Our Innovation
Our Innovation geneType integrates genetic risk and clinical risk to better stratify individual risk. Patients with potentially high risk may exceed actionable clinical guidelines 10 – 15 years earlier than those with low risk 1,2,3 Breast Cancer (BC)1 Colorectal Cancer (CRC)2 Chronic Heart Disease
Slide 19: Our Portfolio – Driving Growth
Our Portfolio − Driving Growth ` ` Moderate CIT Platform in AUS and Revenue USA selling BRC and CRC Expectations Q2 CY 2021 IBX COVID Risk Test Revenue released for sale May 31, Commenced 2021 Q2 CY 2021 Expanding into reimbursable 100% Germline + PRS test space Commercially for Breast Cancer and CR
Slide 20: Significant market opportunity
Significant market opportunity To provide predictive, pre-symptomatic testing to inform lifestyle choices and healthcare discussions Guideline driven, reimbursable for inherited and non inherited disease Near Term Addressable Market GTG Target Market for BRCA Panel + Breast Cancer PRS 281,5505 1st d
Slide 21: Our Innovation - Multi Test
Our Innovation - Multi Test A companion diagnostic PRS to help identify risk of serious disease for up to 70% of Mortalities and Morbidities Committed to continually invest in developing multi population testing solutions Phase 1 Launch 2 Oncology GeneType Multi-test to include Phase 2 Launch 3 Brea
Slide 22: Our Capabilities
01 02 03 04 05 06 Our Vision & Our Markets Our Acquisition Our Channels & Our Portfolio & Our Capabilities Brand Pillars Divisions Innovation 23
Slide 23: Our Capability
Our Capability Dedicated Innovation Hub Developing and capturing the next generation of innovation in genomics Marketing and Positioning Enhanced Sales and Distribution Creating a consumer and patient led Capitalise on Licensing, JV and M&A opportunities infrastructure for a direct to consumer Partn
Slide 24: Targeted and Positioned for deliberate growth
01 02 03 04 05 06 Our Vision & Our Markets Our Acquisition Our Channels & Our Portfolio & Our Capabilities Brand Pillars Divisions Innovation Targeted and Positioned for Focused and Cutting edge Aligned to deliberate growth distinct innovation execute 25
Slide 25: Thank you
Thank you
Slide 26: Appendices
Appendices
Slide 27: Our Intellectual Property
Our Intellectual Property 7 Patents granted in the US 9 Patent families pending • Patent 11,031,098, Computer systems and methods for genomic analysis • Methods for breast cancer risk assessment • Patent 10,683,549, Methods for assessing risk of developing breast cancer • Methods for assessing risk
Slide 28: Board and Management: Sales and Scientific expertise leading GTG
Board and Management: Sales and Scientific expertise leading GTG Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Com, FAICD, FCA, Chairman - Non – Executive Non – Executive Director FGIA, FTIA, F Fin Director Non – Executive Director Dr. Jerzy “George” Muchnicki Erika Spae
Slide 29: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MWGO is MD, MS, FACMG Research & Education Lead, Primary Care Principal Fellow and Professor, Department Regional Medical Director,
Slide 30: Corporate Overview
Corporate Overview Top 50 share registry breakdown Dual Listed on the ASX and Nasdaq Financial Information Other, 20% Share price (AUD) as at 7 September 2021 0.8c ADR price (USD) as at 7 September 2021 $3.37 Board & Management , Ord Share on Issue (M) 9,226 6% ASX 52-week trading (low/high) 0.6/1.4
Slide 31: Defined Terms
Defined Terms Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score - a number associated